# BeOne Medicines Ltd. (ONC)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/beone-medicines-ltd/ JSON: https://steadybase.io/company/beone-medicines-ltd.json Checked Nov 10, 2026. Latest filing read: Nov 5, 2026.

## Company

- Legal name: BeOne Medicines Ltd.
- Ticker: ONC, BEIGF (Nasdaq, OTC)
- SEC CIK: 0001651308
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: Basel
- Fiscal year ends: December 31
- SEC filer category: Large accelerated filer
- Website: beonemedicines.com
- LinkedIn: https://www.linkedin.com/company/beigene
- Next earnings date: Nov 25, 2026 (estimated from past 8-K timing)

## Key facts

- Revenue: $5.3B for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1651308/000162828026011946/0001628280-26-011946-index.html
- Operating income: $447.1M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1651308/000162828026011946/0001628280-26-011946-index.html
- Net income: $286.9M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1651308/000162828026011946/0001628280-26-011946-index.html
- SG&A: $2.1B for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1651308/000162828026011946/0001628280-26-011946-index.html
- Employees: 12,000 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1651308/000162828026011946/bgne-20251231.htm
- Shares outstanding: 1,484,939,031 as of Oct 30, 2026 (10-Q filed Nov 5, 2026). Source: https://www.sec.gov/Archives/edgar/data/1651308/000162828026070477/0001628280-26-070477-index.html
- Auditor: Ernst & Young LLP, Boston, Massachusetts, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1651308/000162828026011946/bgne-20251231.htm

## Business

We are a leading global oncology company discovering and developing innovative treatments that are more accessible to cancer patients worldwide.7 million.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1651308/000162828026011946/bgne-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $5.3B | $447.1M | $286.9M | $2.1B |
| Dec 31, 2024 | $3.8B | -$568.2M | -$644.8M | $1.8B |
| Dec 31, 2023 | $2.5B | -$1.2B | -$881.7M | $1.5B |
| Dec 31, 2022 | $1.4B | -$1.8B | -$2.0B | $1.3B |
| Dec 31, 2021 | $1.2B | -$1.4B | -$1.5B | $990.1M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/beone-medicines-ltd.json

## Officers and directors

- John Oyler, Chief Executive Officer. Source: Form 4 filed Aug 12, 2026, https://www.sec.gov/Archives/edgar/data/1651308/000104204726000019/0001042047-26-000019-index.htm
- Aaron Rosenberg, Chief Financial Officer. LinkedIn: https://linkedin.com/in/arosenberg22. Source: Form 4 filed Aug 5, 2026, https://www.sec.gov/Archives/edgar/data/1651308/000203118226000005/0002031182-26-000005-index.htm
- Xiaobin Wu, President and COO. LinkedIn: https://linkedin.com/in/dr-xiaobin-wu. Source: Form 4 filed Aug 27, 2026, https://www.sec.gov/Archives/edgar/data/1651308/000173945226000011/0001739452-26-000011-index.htm
- Lai Wang, President, Global Head of R&D. Source: Form 4 filed Jun 25, 2026, https://www.sec.gov/Archives/edgar/data/1651308/000185229126000007/0001852291-26-000007-index.htm
- Titus B. Ball, Principal Accounting Officer. Source: Form 4 filed Sep 3, 2026, https://www.sec.gov/Archives/edgar/data/1651308/000167562826000003/0001675628-26-000003-index.htm
- Chan Henry Lee, SVP, General Counsel. Source: Form 4 filed Aug 13, 2026, https://www.sec.gov/Archives/edgar/data/1651308/000198064826000024/0001980648-26-000024-index.htm
- Titus Ball, Chief Accounting Officer. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1651308/000162828026011946/bgne-20251231.htm
- Alessandro Riva, Director. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1651308/000162828026011946/bgne-20251231.htm
- Anthony C. Hooper, Director. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1651308/000162828026011946/bgne-20251231.htm
- Corazon (Corsee) D. Sanders, Director. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1651308/000162828026011946/bgne-20251231.htm
- Margaret Dugan, Director. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1651308/000162828026011946/bgne-20251231.htm
- Michael Goller, Director. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1651308/000162828026011946/bgne-20251231.htm
- Olivier Brandicourt, Director. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1651308/000162828026011946/bgne-20251231.htm
- Qingqing Yi, Director. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1651308/000162828026011946/bgne-20251231.htm
- Ranjeev Krishana, Director. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1651308/000162828026011946/bgne-20251231.htm
- Shalini Sharp, Director. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1651308/000162828026011946/bgne-20251231.htm
- Xiaodong Wang, Director. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1651308/000162828026011946/bgne-20251231.htm
- Chan Lee, Senior Vice President, General Counsel and Corporate Secretary. Source: DEF 14A filed Apr 28, 2026, https://www.sec.gov/Archives/edgar/data/1651308/000110465926049655/tm261479-4_def14a.htm

## Recent 8-K events

- Nov 5, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1651308/000162828026070469/bgne-20261105.htm
- Aug 26, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1651308/000165130826000025/bgne-20260826.htm
- Aug 5, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1651308/000162828026052877/bgne-20260805.htm
- Jun 26, 2026: Item 8.01, Other events. Source: https://www.sec.gov/Archives/edgar/data/1651308/000165130826000020/bgne-20260626.htm
- Jun 11, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 5.07, Submission of matters to a vote of security holders; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1651308/000165130826000017/bgne-20260611.htm
- May 15, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1651308/000165130826000012/bgne-20260513.htm
- May 6, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1651308/000162828026030866/bgne-20260506.htm
- Apr 14, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1651308/000165130826000008/bgne-20260414.htm
- Feb 26, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1651308/000162828026011941/bgne-20260226.htm
- Dec 19, 2025: Item 1.02, Termination of a material definitive agreement. Source: https://www.sec.gov/Archives/edgar/data/1651308/000165130825000153/bgne-20251216.htm

## Insider trades (Form 4)

- Nov 5, 2026: Chan Henry Lee (SVP, General Counsel) sold 1,115 shares, about $446,910. Source: https://www.sec.gov/Archives/edgar/data/1651308/000198064826000029/0001980648-26-000029-index.htm
- Oct 27, 2026: Xiaodong Wang (Director) sold 31,028 shares, about $11.3M. Source: https://www.sec.gov/Archives/edgar/data/1651308/000166298226000008/0001662982-26-000008-index.htm
- Oct 13, 2026: Xiaodong Wang (Director) sold 31,027 shares, about $10.9M. Source: https://www.sec.gov/Archives/edgar/data/1651308/000166298226000006/0001662982-26-000006-index.htm
- Sep 30, 2026: Chan Henry Lee (SVP, General Counsel) sold 1,115 shares, about $418,125. Source: https://www.sec.gov/Archives/edgar/data/1651308/000198064826000027/0001980648-26-000027-index.htm
- Sep 28, 2026: Xiaodong Wang (Director) sold 31,028 shares, about $11.3M. Source: https://www.sec.gov/Archives/edgar/data/1651308/000166298226000004/0001662982-26-000004-index.htm
- Sep 8, 2026: Xiaodong Wang (Director) sold 38,287 shares, about $13.4M. Source: https://www.sec.gov/Archives/edgar/data/1651308/000166298226000002/0001662982-26-000002-index.htm
- Sep 1, 2026: Titus B. Ball (Principal Accounting Officer) sold 132 shares, about $46,974. Source: https://www.sec.gov/Archives/edgar/data/1651308/000167562826000003/0001675628-26-000003-index.htm
- Aug 25, 2026: Xiaobin Wu (President and COO) sold 280 shares, about $106,400. Source: https://www.sec.gov/Archives/edgar/data/1651308/000173945226000011/0001739452-26-000011-index.htm
- Aug 12, 2026: John Oyler (Chief Executive Officer) sold 240,810 shares, about $86.5M. Source: https://www.sec.gov/Archives/edgar/data/1651308/000104204726000019/0001042047-26-000019-index.htm
- Aug 11, 2026: Chan Henry Lee (SVP, General Counsel) sold 2,666 shares, about $959,760. Source: https://www.sec.gov/Archives/edgar/data/1651308/000198064826000024/0001980648-26-000024-index.htm
- Aug 3, 2026: Aaron Rosenberg (Chief Financial Officer) sold 1,157 shares, about $361,817. Source: https://www.sec.gov/Archives/edgar/data/1651308/000203118226000005/0002031182-26-000005-index.htm
- Jul 30, 2026: Chan Henry Lee (SVP, General Counsel) sold 1,044 shares, about $337,932. Source: https://www.sec.gov/Archives/edgar/data/1651308/000198064826000021/0001980648-26-000021-index.htm
- Jul 22, 2026: Chan Henry Lee (SVP, General Counsel) sold 1,669 shares, about $542,425. Source: https://www.sec.gov/Archives/edgar/data/1651308/000198064826000019/0001980648-26-000019-index.htm
- Jul 21, 2026: John Oyler (Chief Executive Officer) sold 109,713 shares, about $34.6M. Source: https://www.sec.gov/Archives/edgar/data/1651308/000104204726000017/0001042047-26-000017-index.htm
- Jul 17, 2026: John Oyler (Chief Executive Officer) sold 64,628 shares, about $20.2M. Source: https://www.sec.gov/Archives/edgar/data/1651308/000104204726000015/0001042047-26-000015-index.htm

## What management said

- "Our strong third quarter results and raised full-year guidance reflect continued rapid global growth and leadership in hematology, anchored by our foundational BTK inhibitor BRUKINSA, which drives powerful and sustained responses in patients, and now joined by our next-generation BCL2 inhibitor BEQALZI. We look forward to multiple catalysts in the coming months from one of the deepest pipelines in oncology, spanning hematology and solid tumors, accelerated by our differentiat" John V. Oyler, Co-Founder, Chairman, and CEO, BeOne (8-K filed Nov 5, 2026). Source: https://www.sec.gov/Archives/edgar/data/1651308/000162828026070469/exhibit991-q32026earningsr.htm

## Latest filings

- 8-K filed Aug 26, 2026: https://www.sec.gov/Archives/edgar/data/1651308/000165130826000025/bgne-20260826.htm
- 10-K filed Feb 26, 2026: https://www.sec.gov/Archives/edgar/data/1651308/000162828026011946/bgne-20251231.htm
- 10-Q filed Aug 5, 2026: https://www.sec.gov/Archives/edgar/data/1651308/000162828026052878/bgne-20260630.htm
- DEF 14A filed Apr 28, 2026: https://www.sec.gov/Archives/edgar/data/1651308/000110465926049655/tm261479-4_def14a.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/